title: The discovery of new spirocyclic muscarinic M3 antagonists.
authors.affiliation: Department of Chemistry, AstraZeneca R&D Charnwood, Loughborough, Leicestershire, UK. mike.stocks@astrazeneca.com
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Stocks
authors.forename: Lilian
authors.initials: L
authors.lastname: Alcaraz
authors.forename: Andrew
authors.initials: A
authors.lastname: Bailey
authors.forename: Keith
authors.initials: K
authors.lastname: Bowers
authors.forename: David
authors.initials: D
authors.lastname: Donald
authors.forename: Helen
authors.initials: H
authors.lastname: Edwards
authors.forename: Fraser
authors.initials: F
authors.lastname: Hunt
authors.forename: Nicholas
authors.initials: N
authors.lastname: Kindon
authors.forename: Garry
authors.initials: G
authors.lastname: Pairaudeau
authors.forename: Jill
authors.initials: J
authors.lastname: Theaker
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Warner
mesh_terms: D000818:Animals; D004353:Drug Evaluation, Preclinical; D022781:Hepatocytes / Q000378:metabolism; D006801:Humans; D008861:Microsomes / Q000378:metabolism; D051381:Rats; D043587:Receptor, Muscarinic M3 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013141:Spiro Compounds / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology
chemical_list: D043587:Receptor, Muscarinic M3; D013141:Spiro Compounds